MX2020007552A - Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio. - Google Patents

Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio.

Info

Publication number
MX2020007552A
MX2020007552A MX2020007552A MX2020007552A MX2020007552A MX 2020007552 A MX2020007552 A MX 2020007552A MX 2020007552 A MX2020007552 A MX 2020007552A MX 2020007552 A MX2020007552 A MX 2020007552A MX 2020007552 A MX2020007552 A MX 2020007552A
Authority
MX
Mexico
Prior art keywords
sodium bicarbonate
pharmaceutical composition
stable pharmaceutical
esomeprazole
relates
Prior art date
Application number
MX2020007552A
Other languages
English (en)
Inventor
Jong Lae Lim
Min Soo Kim
Shin Jung Park
Jong Seo Choi
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67395505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020007552(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of MX2020007552A publication Critical patent/MX2020007552A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica estable que comprende omeprazol, su enantiómero o su sal farmacéuticamente aceptable, y bicarbonato de sodio. Específicamente, la presente invención se relaciona con una composición farmacéutica con estabilidad mejorada que comprende una dosis baja de bicarbonato de sodio, de modo que tiene una tasa de disolución y disponibilidad mejoradas y también reduce los efectos secundarios que resultan de una alta dosis de bicarbonato de sodio.
MX2020007552A 2018-01-29 2019-01-09 Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio. MX2020007552A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180010980A KR102080023B1 (ko) 2018-01-29 2018-01-29 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
PCT/KR2019/000309 WO2019146937A1 (en) 2018-01-29 2019-01-09 Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate

Publications (1)

Publication Number Publication Date
MX2020007552A true MX2020007552A (es) 2020-09-09

Family

ID=67395505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007552A MX2020007552A (es) 2018-01-29 2019-01-09 Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio.

Country Status (6)

Country Link
US (1) US11813285B2 (es)
JP (1) JP7003279B2 (es)
KR (1) KR102080023B1 (es)
CN (1) CN111727036B (es)
MX (1) MX2020007552A (es)
WO (1) WO2019146937A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
US12251375B2 (en) 2018-08-23 2025-03-18 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate
WO2021020771A1 (ko) * 2019-07-26 2021-02-04 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102494141B1 (ko) * 2019-10-18 2023-02-01 주식회사 대웅테라퓨틱스 프로톤 펌프 저해제 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 및 이의 제조방법
KR20220028789A (ko) 2020-08-31 2022-03-08 진양제약주식회사 에스오메프라졸 함유 다층 정제
KR102809183B1 (ko) * 2021-09-06 2025-05-20 한국유나이티드제약 주식회사 라베프라졸과 탄산수소나트륨을 포함하는 약학조성물
KR20240030479A (ko) 2022-08-31 2024-03-07 한올바이오파마주식회사 에스오메프라졸 및 제산제를 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
KR100274698B1 (ko) 1992-09-29 2000-12-15 손정삼 다층 알칼리 코팅에 의한 오메프라졸의 경구제제 및 그 제조방법
DK0723436T3 (da) 1994-07-08 2001-11-26 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
KR960003605A (ko) 1994-07-19 1996-02-23 김충식 해조류(海藻類)성분이 함유된 저염(低鹽) 재제염의 제조방법
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
JP2003073270A (ja) 2001-08-30 2003-03-12 Nisshin Seiyaku Kk 安定性および溶出性の良好なプラバスタチンナトリウム錠
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US20050220870A1 (en) 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1646404B1 (en) 2003-07-11 2010-01-13 AstraZeneca AB Solid composition comprising a proton pump inhibitor
AR045068A1 (es) 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
KR100581967B1 (ko) 2003-12-18 2006-05-22 한국유나이티드제약 주식회사 소화성 궤양 치료를 위한 프로톤펌프 저해제와클래리스로마이신을 함유하는 이중 펠렛 제제 및 그의제조방법
CA2558535A1 (en) 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
EP1742630A4 (en) 2004-04-16 2010-01-20 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND PROKINETIC AGENT
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2008500365A (ja) 2004-05-25 2008-01-10 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにその製造方法および使用方法
EP1841460A2 (en) 2004-06-18 2007-10-10 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
CH698658B1 (de) 2006-04-24 2009-09-30 Mepha Ag Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CN101002769A (zh) * 2007-01-12 2007-07-25 广东华南药业有限公司 奥美拉唑组合物制剂
CN101259108A (zh) 2007-03-09 2008-09-10 上海艾力斯医药科技有限公司 包含酸不稳定药物的双单元片剂
CN100490790C (zh) 2007-04-28 2009-05-27 杭州民生药业集团有限公司 一种奥美拉唑肠溶微丸胶囊及其制备方法
CN104940127A (zh) 2007-09-28 2015-09-30 西梯茜生命工学股份有限公司 含有埃索美拉唑的药物组合物
JP2011512416A (ja) 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
EP2313088A2 (en) 2008-08-11 2011-04-27 Mepha GmbH Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
US9220698B2 (en) 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
KR20100066742A (ko) 2008-12-10 2010-06-18 삼일제약주식회사 안정화된 프로톤 펌프 억제제 함유 약학 조성물
WO2010096814A1 (en) 2009-02-23 2010-08-26 Eurand, Inc. Controlled-release compositions comprising a proton pump inhibitor
KR101270751B1 (ko) 2010-05-06 2013-06-07 (주)비씨월드제약 위 체류 및 방출 조절을 위한 조성물
CN102078616A (zh) 2011-01-28 2011-06-01 北京虹湾医药技术有限公司 埃索美拉唑碳酸氢钠组合物
CN102397277A (zh) 2011-11-17 2012-04-04 成都欣捷高新技术开发有限公司 包含埃索美拉唑的药物组合物
KR101907690B1 (ko) 2012-04-12 2018-10-15 한미약품 주식회사 비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 약제학적 복합제제 및 이의 제조방법
CN103006691B (zh) 2013-01-05 2014-10-08 青岛大学 一种含奥美拉唑碳酸氢钠复方胶囊制剂
EP2964270A4 (en) 2013-02-21 2017-03-22 University Of Rochester Methods for evaluating brain-wide paravascular pathway for waste clearance function and methods for treating neurodegenerative disorders based thereon
CN103599082A (zh) 2013-04-05 2014-02-26 黑龙江福和华星制药集团股份有限公司 奥美拉唑和碳酸氢钠包芯片
CN103784414B (zh) 2013-12-18 2018-01-30 北京华禧联合科技发展有限公司 一种埃索美拉唑肠溶片及其制备方法
KR102242670B1 (ko) 2014-01-09 2021-04-20 일동제약(주) 둘록세틴이 함유된 안정한 다중코팅 정제 조성물
CN103860584B (zh) 2014-02-25 2015-09-30 厦门恩成制药有限公司 一种奥美拉唑碳酸氢钠胶囊的制作方法
CN103845734A (zh) 2014-03-20 2014-06-11 辽宁亿灵科创生物医药科技有限公司 埃索美拉唑药物组合物及其制剂
KR101723266B1 (ko) 2014-08-13 2017-04-05 영남대학교 산학협력단 비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 경구용 속방형 조성물 및 그 제조방법
WO2016102661A1 (en) 2014-12-23 2016-06-30 Krka, D.D., Novo Mesto Pharmaceutical tablet composition
CN204428461U (zh) 2014-12-29 2015-07-01 黑龙江福和华星制药集团股份有限公司 埃索美拉唑碳酸氢钠片中片
KR102289011B1 (ko) 2014-12-31 2021-08-11 한미약품 주식회사 비스테로이드성 항염증제 및 프로톤 펌프 저해제를 포함하는 경구용 서방성 복합제제
CN104523746B (zh) 2015-02-02 2017-07-07 长春海悦药业股份有限公司 一种埃索美拉唑镁碳酸氢钠组合物
MY191574A (en) 2015-02-10 2022-06-30 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
KR20160124368A (ko) 2015-04-17 2016-10-27 대원제약주식회사 프로피온산 계열의 비스테로이드성 항염증 약물(nsaid) 및 프로톤 펌프 저해제(ppi)를 함유하는 생체이용률이 증진된 약제학적 조성물
KR102408645B1 (ko) 2015-12-24 2022-06-14 (주)휴온스 안정성이 증가된 에스오메프라졸 함유 이중코팅정 조성물 및 이의 제조방법
CA3010062C (en) 2016-01-16 2023-06-27 D.Y. Seligman Consulting Ltd. Low carbohydrate sugar fondant
KR101841662B1 (ko) * 2016-06-02 2018-03-23 동화약품주식회사 프로톤 펌프 저해제의 고체분산체 및 이를 포함하는 약제학적 조성물
JP6859043B2 (ja) 2016-07-22 2021-04-14 キヤノン株式会社 液体吐出ヘッド
KR101907116B1 (ko) 2016-07-25 2018-10-11 한미약품 주식회사 에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형
KR101911021B1 (ko) 2017-02-27 2018-10-25 한국과학기술원 필름기반 통합칩 및 이의 핵산 검출 방법
KR102227486B1 (ko) 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
KR20190037182A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 에스오메프라졸 및 그의 약학적으로 허용가능한 염을 함유하는 다중 투여 단위 정제를 포함한 약제학적 조성물 및 그의 제조 방법
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
US12251375B2 (en) 2018-08-23 2025-03-18 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate

Also Published As

Publication number Publication date
WO2019146937A1 (en) 2019-08-01
KR20190091879A (ko) 2019-08-07
CN111727036A (zh) 2020-09-29
US20210030786A1 (en) 2021-02-04
JP7003279B2 (ja) 2022-01-20
JP2021512081A (ja) 2021-05-13
KR102080023B1 (ko) 2020-02-21
US11813285B2 (en) 2023-11-14
BR112020014306A2 (pt) 2020-12-08
CN111727036B (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
MX2020007552A (es) Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio.
MX2020007554A (es) Formulacion farmaceutica que comprende esomeprazol y bicarbonato de sodio.
MX2021014509A (es) Composiciones farmaceuticas que comprenden meloxicam.
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MY187047A (en) Selective pyy compounds and uses thereof
EA201792591A1 (ru) Фармацевтические препараты
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX387639B (es) Formulaciones farmacéuticas de compuesto de piridinio y un potenciador de la permeabilidad o una base.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
ZA202203563B (en) Pediatric suspension formulation
MX2022000968A (es) Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio.
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
MY188302A (en) Solid pharmaceutical composition comprising amlodipine and losartan
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
PH12016502527B1 (en) Stabilized desmopressin
EA201691763A1 (ru) Стабильная быстрорастворимая лекарственная форма, содержащая амоксициллин и клавулановую кислоту
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
TR201721065A2 (tr) Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar
SG11201810308TA (en) Oral tipepidine preparation